These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 26102014)
1. The Real-World Treatment of Hemorrhages Associated With Dabigatran and Rivaroxaban: A Multicenter Evaluation. Pahs L; Beavers C; Schuler P Crit Pathw Cardiol; 2015 Jun; 14(2):53-61. PubMed ID: 26102014 [TBL] [Abstract][Full Text] [Related]
2. A Review of and Recommendations for the Management of Patients With Life-Threatening Dabigatran-Associated Hemorrhage: A Single-Center University Hospital Experience. Kumar R; Smith RE; Henry BL J Intensive Care Med; 2015 Dec; 30(8):462-72. PubMed ID: 24668159 [TBL] [Abstract][Full Text] [Related]
3. Clinical experience of life-threatening dabigatran-related bleeding at a large, tertiary care, academic medical center: a case series. Ross B; Miller MA; Ditch K; Tran M J Med Toxicol; 2014 Jun; 10(2):223-8. PubMed ID: 24385325 [TBL] [Abstract][Full Text] [Related]
4. Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation. Sin JH; Berger K; Lesch CA J Crit Care; 2016 Dec; 36():166-172. PubMed ID: 27546767 [TBL] [Abstract][Full Text] [Related]
5. Management of Major Bleeding Events in Patients Treated With Dabigatran for Nonvalvular Atrial Fibrillation: A Retrospective, Multicenter Review. Milling TJ; Fromm C; Ganetsky M; Pallin DJ; Cong J; Singer AJ Ann Emerg Med; 2017 May; 69(5):531-540. PubMed ID: 28196608 [TBL] [Abstract][Full Text] [Related]
6. Direct Oral Anticoagulant- or Warfarin-Related Major Bleeding: Characteristics, Reversal Strategies, and Outcomes From a Multicenter Observational Study. Xu Y; Schulman S; Dowlatshahi D; Holbrook AM; Simpson CS; Shepherd LE; Wells PS; Giulivi A; Gomes T; Mamdani M; Khuu W; Frymire E; Johnson AP; Chest; 2017 Jul; 152(1):81-91. PubMed ID: 28219635 [TBL] [Abstract][Full Text] [Related]
7. Modified HAS-BLED Score and Risk of Major Bleeding in Patients Receiving Dabigatran and Rivaroxaban: A Retrospective, Case-Control Study. Tsu LV; Berry A; Wald E; Ehrlich C Consult Pharm; 2015 Jul; 30(7):395-402. PubMed ID: 26173191 [TBL] [Abstract][Full Text] [Related]
8. Management of Factor Xa inhibitor-associated life-threatening major hemorrhage: A retrospective multi-center analysis. Milling TJ; Clark CL; Feronti C; Song SS; Torbati SS; Fermann GJ; Weiss J; Patel D Am J Emerg Med; 2018 Mar; 36(3):396-402. PubMed ID: 28843518 [TBL] [Abstract][Full Text] [Related]
9. Emergency admissions for major haemorrhage associated with direct oral anticoagulants. Bouget J; Oger E Thromb Res; 2015 Dec; 136(6):1190-4. PubMed ID: 26545315 [TBL] [Abstract][Full Text] [Related]
10. Treatment of dabigatran-associated bleeding: case report and review of the literature. Harinstein LM; Morgan JW; Russo N J Pharm Pract; 2013 Jun; 26(3):264-9. PubMed ID: 23160864 [TBL] [Abstract][Full Text] [Related]
11. Effect of low and moderate dose FEIBA to reverse major bleeding in patients on direct oral anticoagulants. Dager WE; Roberts AJ; Nishijima DK Thromb Res; 2019 Jan; 173():71-76. PubMed ID: 30476716 [TBL] [Abstract][Full Text] [Related]
12. Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study. Schulman S; Gross PL; Ritchie B; Nahirniak S; Lin Y; Lieberman L; Carrier M; Crowther MA; Ghosh I; Lazo-Langner A; Zondag M; Thromb Haemost; 2018 May; 118(5):842-851. PubMed ID: 29564837 [TBL] [Abstract][Full Text] [Related]
13. Management of anticoagulation in patients with acute gastrointestinal bleeding. Radaelli F; Dentali F; Repici A; Amato A; Paggi S; Rondonotti E; Dumonceau JM Dig Liver Dis; 2015 Aug; 47(8):621-7. PubMed ID: 25935464 [TBL] [Abstract][Full Text] [Related]
14. Safety of early initiation of rivaroxaban or dabigatran after thrombolysis in acute ischemic stroke. Ritzenthaler T; Derex L; Davenas C; Bnouhanna W; Farghali A; Mechtouff L; Cho TH; Nighoghossian N Rev Neurol (Paris); 2015 Sep; 171(8-9):613-5. PubMed ID: 25857461 [TBL] [Abstract][Full Text] [Related]
15. Coagulation Factor Concentrates Fail to Restore Alterations in Fibrin Formation Caused by Rivaroxaban or Dabigatran in Studies With Flowing Blood From Treated Healthy Volunteers. Arellano-Rodrigo E; Lopez-Vilchez I; Galan AM; Molina P; Reverter JC; Carné X; Villalta J; Tassies D; Lozano M; Díaz-Ricart M; Escolar G Transfus Med Rev; 2015 Oct; 29(4):242-9. PubMed ID: 26364029 [TBL] [Abstract][Full Text] [Related]
16. Reversal of dabigatran-associated major bleeding with activated prothrombin concentrate: A prospective cohort study. Schulman S; Ritchie B; Nahirniak S; Gross PL; Carrier M; Majeed A; Hwang HG; Zondag M; Thromb Res; 2017 Apr; 152():44-48. PubMed ID: 28222322 [TBL] [Abstract][Full Text] [Related]
17. Role of Hypertension and Other Clinical Variables in Prognostication of Patients Presenting to the Emergency Department With Major Bleeding Events. Conti A; Molesti D; Bianchi S; Catarzi S; Mazzucchelli M; Covelli A; Tognarelli A; Perrotta ME; Pampana A; Orlandi G; Dell'Amico I; Baratta A; Arena G; Torri T Crit Pathw Cardiol; 2018 Sep; 17(3):139-146. PubMed ID: 30044254 [TBL] [Abstract][Full Text] [Related]
18. Reversal of direct oral anticoagulants. Zhang XY; Desborough MJ; Shapiro S Br J Hosp Med (Lond); 2017 Mar; 78(3):165-169. PubMed ID: 28277769 [TBL] [Abstract][Full Text] [Related]
19. [Clinical perspectives on the management of bleeding in patients on oral anticoagulants: the DECOVER Study (DElphi Consensus on oral COagulation and therapy action reVERsal)]. Vicente V; Martín A; Lecumberri R; Coll-Vinent B; Suero C; González-Porras JR; Marco P; Mateo J; Roldán V; Soulard S; Crespo C; Camats M; Emergencias; 2017 Feb; 29(1):18-26. PubMed ID: 28825264 [TBL] [Abstract][Full Text] [Related]
20. Dabigatran and bleeding: still an emergent situation? Van Heukelom J; Lal Y Am J Med Sci; 2013 Sep; 346(3):259. PubMed ID: 23698156 [No Abstract] [Full Text] [Related] [Next] [New Search]